Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.74), $0.40 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $166.8 million versus the consensus estimate of $197.77 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Seaport Global Securities Upgrades Analog Devices (ADI) to Buy
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c